Concorde Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Concorde Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,045	Closed	-$442K	–	160
2017 Q3	$442K	Sell	5,045 -871	-15%	-$69.8K	0.38%	76
2017 Q2	$456K	Sell	5,916 -941	-14%	-$66.7K	0.62%	61
2017 Q1	$469K	Sell	6,857 -634	-8%	-$42.6K	0.77%	44
2016 Q4	$388K	Sell	7,491 -3,468	-32%	-$214K	0.7%	54
2016 Q3	$726K	Sell	10,959 -1,278	-10%	-$79.1K	0.91%	32
2016 Q2	$607K	Sell	12,237 -3,334	-21%	-$183K	0.6%	38
2016 Q1	$815K	Sell	15,571 -3,392	-18%	-$176K	0.94%	30
2015 Q4	$1.33M	Sell	18,963 -407	-2%	-$27.8K	1.48%	17
2015 Q3	$1.21M	Buy	19,370 +1,334	+7%	+$105K	2.04%	12
2015 Q2	$1.52M	Buy	+18,036	New	+$1.4M	1.93%	15

Other funds holding XBI

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Concorde Asset Management's XBI Position: Q4 2017 in Review

Concorde Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2017, closing a stake of 5,045 shares — an estimated $442K sold.

Concorde Asset Management first reported a position in XBI in Q2 2015 and held it in 10 quarters. The position peaked at $1.52M in Q2 2015. 397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

Concorde Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2017 after selling out during the quarter.
Concorde Asset Management sold 5,045 State Street SPDR S&P Biotech ETF shares in Q4 2017, an estimated $442K.
Concorde Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and held it in 10 quarters.
Concorde Asset Management's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q2 2015.
397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on Concorde Asset Management's 13F filing for Q4 2017, filed 23 Jan 2018.